Rigel Pharmaceuticals (RIGL) Gross Margin (2018 - 2026)
Rigel Pharmaceuticals' (RIGL) quarterly Gross Margin came in at 92.17% in Q1 2026, up 44.0% year-on-year from 64.01% in Q1 2025, and up 0.77% quarter-over-quarter from 91.47% in Q4 2025.
Rigel Pharmaceuticals (RIGL) Gross Margin (2018 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Gross Margin history runs 9 years deep, the most recent figure standing at 92.17% for Q1 2026.
- On a quarterly basis, Gross Margin rose 44.0% year-over-year to 92.17% in Q1 2026; TTM through Mar 2026 was 93.39%, a 375.0% increase from a year earlier, with the FY2025 full-year figure at 93.33%, up 373.0% from the prior year.
- Gross Margin advanced to 92.17% in Q1 2026 per RIGL's latest filing, from 91.47% in the prior quarter.
- Across five years, Gross Margin topped out at 99.33% in Q4 2022 and bottomed at 85.49% in Q3 2024.
- The 5-year median for Gross Margin is 93.16% (2025), against an average of 93.9%.
- Across the five-year window, Gross Margin tumbled 1000 bps in 2024 and jumped 767 bps in 2025, its largest moves.
- Year by year, Gross Margin stood at 99.33% in 2022, then decreased by 10 bps to 89.41% in 2023, then climbed by 1 bps to 89.95% in 2024, then gained by 2 bps to 91.47% in 2025, then gained by 1 bps to 92.17% in 2026.
- Per Business Quant, the three latest RIGL Gross Margin figures stand at 92.17% (Q1 2026), 91.47% (Q4 2025), and 93.16% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Rigel Pharmaceuticals | 681.25 Mn | 534.56 Mn | 54.21 Mn | 92.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.17% |
| Dec 31, 2025 | 91.47% |
| Sep 30, 2025 | 93.16% |
| Jun 30, 2025 | 95.57% |
| Mar 31, 2025 | 91.73% |
| Dec 31, 2024 | 89.95% |
| Sep 30, 2024 | 85.49% |
| Jun 30, 2024 | 92.38% |
| Mar 31, 2024 | 93.14% |
| Dec 31, 2023 | 89.41% |
| Sep 30, 2023 | 95.49% |
| Jun 30, 2023 | 96.00% |
| Mar 31, 2023 | 96.25% |
| Dec 31, 2022 | 99.33% |
| Sep 30, 2022 | 98.88% |
| Jun 30, 2022 | 96.53% |
| Mar 31, 2022 | 99.28% |
| Dec 31, 2021 | 97.61% |
| Sep 30, 2021 | 99.30% |
| Jun 30, 2021 | 99.51% |